Is bioAffinity Technologies, Inc. (BIAFW) a Buy, Sell, or Hold?
NASDAQ : BIAFW
bioAffinity Technologies, Inc.
$0.07 USD
$0 (0.0%)
- Volume
- 22
- Average Volume
- 1.66K
- Market Capitalization
- $2.49M
- P/E Ratio
- -0.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.47
- Year Low
- $0.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.44
Company Overview
NASDAQ
Maria Zannes
Medical - Specialties
Healthcare
BIAFW
57
US
USD
Liquidity Metrics
0.38
1.44
1.41
0.91
0.00
Sales & Valuation
$6.16M
0.54
0.71
-0.28
-2.20
Profitability
-$8.66
-$14.91M
-257.33%
-257.23%
-257.27%
-199.30%
P/E Metrics
-0.06
0.00
0.00
Analyst Price Target & Rating
3/5
0 Analysts
%
Financial Health Scores
-19.09
3/9
$1.18M
$7.62M
$3.85M
-$15.12M
Key Metrics (TTM)
$2.21M
0.37
-0.15
1.44
-257.27%
-237.93%
-569.67%
-358.87%
-40 days
Company Executives
| Name | Title |
|---|---|
| Maria Zannes | Founder, President, Chief Executive Officer & Director |
| Timothy Zannes | Executive Vice President, Secretary & General Counsel |
| William Bauta | Chief Science Officer |
| James Michael Edwards | Chief Financial Officer |
| Julie Anne Overton | Director of Communications |
| Steven Girgenti | Founder & Executive Chairman of the Board |
| Xavier T. Reveles | Chief Operating Officer |
| Dallas J. Coleman | Vice President of sales |
| Gordon Downie | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About bioAffinity Technologies, Inc. (NASDAQ:BIAFW) Stock
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas. ...
Frequently Asked Questions
-
What is the current bioAffinity Technologies, Inc. (BIAFW) stock price?
-
bioAffinity Technologies, Inc.(NASDAQ:BIAFW) stock price is $0.07 in the last trading session. During the trading session, BIAFW stock reached the peak price of $0.47 while $0.0556 was the lowest point it dropped to. The percentage change in BIAFW stock occurred in the recent session was 0.0% while the dollar amount for the price change in BIAFW stock was $0.
-
BIAFW's industry and sector of operation?
-
The NASDAQ listed BIAFW is part of Medical - Specialties industry that operates in the broader Healthcare sector.
-
Who are the executives of BIAFW?
-
Maria Zannes | Founder, President, Chief Executive Officer & Director
Timothy Zannes | Executive Vice President, Secretary & General Counsel
William Bauta | Chief Science Officer
James Michael Edwards | Chief Financial Officer
Julie Anne Overton | Director of Communications -
How many employees does BIAFW have?
-
Number of BIAFW employees currently stands at 57. BIAFW operates from 3300 Nacogdoches Road, San Antonio, TX 78217, US.
-
Link for BIAFW official website?
-
Official Website of BIAFW is: http://www.bioaffinitytech.com
-
How do I contact BIAFW?
-
BIAFW could be contacted at phone #+1 210 698 5334 and can also be accessed through its website. BIAFW operates from 3300 Nacogdoches Road, San Antonio, TX 78217, US.
-
How many shares of BIAFW are traded daily?
-
The average number of BIAFW shares traded daily for last 3 months was 1.66K.
-
What is the market cap of BIAFW currently?
-
The market value of BIAFW currently stands at $2.49M with its latest stock price at $0.07